Bristol Myers Commits $2.3 Billion to Flexible Houston Drug Campus

Bristol Myers Squibb will spend about $2.3 billion on a modular drug-manufacturing campus in Houston. The 600,000-square-foot site will make small molecules, biologics and antibody-drug conjugates.

NYSE:BMY · Pharmaceuticals · Stock Market
Bristol Myers Squibb (NYSE:BMY) faces valuation test Monday as report of potential partnership emerges

Bristol Myers Squibb (NYSE:BMY) faces valuation test Monday as report of potential partnership emerges

Bristol Myers Squibb Company started Monday following reports of a potential major deal. According to the Financial Times, AstraZeneca PLC considered a merger valued at close to $400 billion. AstraZeneca declined to comment. Bristol Myers did not immediately provide a response, and Reuters was unable to independently confirm the story. U.S. financial markets were closed Sunday.
2 August 2026
···
AstraZeneca (NYSE:AZN)–Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value

AstraZeneca (NYSE:AZN)–Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value

A potential deal under discussion could create one of the biggest mergers in the pharmaceutical sector. The Financial Times reported that talks have occurred over the past few months. As of Friday, the combined market value was $396.4 billion. Reuters has not confirmed the report, and there is no guarantee that a deal will be reached.
2 August 2026
···
Amazon Shares Slip After $17.5 Billion AI Loan Draws Focus to AMZN Cash Flow

Amazon takes number one spot on 2026 Fortune 500; regional shifts seen

Amazon has taken the No. 1 spot on the 2026 Fortune 500, Fortune said, unseating Walmart after 13 years at the top. The change put Amazon ahead for the first time in more than a decade and drove shifts in regional tallies for Pennsylvania, New Jersey and New England. Fortune’s 72nd annual list put the collective revenue at $21.0 trillion, with profits at $2.1 trillion and a workforce of 30.5 million worldwide.
15 June 2026
···········
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson on Tuesday said it’s filed with the European Medicines Agency to expand Tecvayli’s EU label, aiming to allow the therapy as a single agent for adults with relapsed or refractory multiple myeloma who’ve already had at least one prior treatment. That would move the drug up in the treatment sequence for the blood cancer, where, according to the company, patients still encounter some of the toughest care gaps.
10 March 2026
···
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid.
18 January 2026
····
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb Company enters the final trading stretch of 2025 with investors balancing a defensive “big pharma” profile and above-market income appeal against policy headlines and the long-running question hanging over the name: how quickly can new launches and pipeline catalysts offset upcoming loss-of-exclusivity pressure in key franchises?
28 December 2025
·
Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb Company heads into the final week of 2025 with U.S. markets shut for the weekend and investor attention shifting to what could matter most when trading resumes Monday: year-end positioning, the company’s next dividend timeline, the next earnings checkpoint, and a set of 2026 regulatory and pipeline milestones that could influence sentiment around the stock.
27 December 2025
···
1 2 3
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.